Recently, the State Drug Administration approved the listing of ritavirbimab injections declared by Zhuhai Tinomaibo Pharmaceutical Co., Ltd. through a priority review and approval procedure to prevent lower respiratory infections caused by RSV in newborns and infants about to enter or be born during the first respiratory syncytial virus epidemic season. The launch of this variety provides new options for those concerned.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.